LONDON, Mar 28: Pfizer suffered a second rejection in two days from Britain’s health cost watchdog NICE as its new kidney cancer drug Inlyta was turned down for use on the state health service. The National Institute for Health and Clinical Excellence (NICE) said on Thursday the new treatment was not a cost-effective use of National Health Service resources. (agencies)
Follow our WhatsApp channel